Single User License
INR 101130
Site License
INR 202260
Corporate User License
INR 303390

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Bristol-Myers Squibb Company-Product Pipeline Review-2015

Bristol-Myers Squibb Company-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Bristol-Myers Squibb Company-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Bristol-Myers Squibb Company-Product Pipeline Review-2015', provides an overview of the Bristol-Myers Squibb Company's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bristol-Myers Squibb Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Bristol-Myers Squibb Company including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Bristol-Myers Squibb Company's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Bristol-Myers Squibb Company's pipeline products

Reasons To Buy

Evaluate Bristol-Myers Squibb Company's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Bristol-Myers Squibb Company in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Bristol-Myers Squibb Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Bristol-Myers Squibb Company and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bristol-Myers Squibb Company

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Bristol-Myers Squibb Company and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Bristol-Myers Squibb Company Snapshot 6

Bristol-Myers Squibb Company Overview 6

Key Information 6

Key Facts 6

Bristol-Myers Squibb Company-Research and Development Overview 7

Key Therapeutic Areas 7

Bristol-Myers Squibb Company-Pipeline Review 16

Pipeline Products by Stage of Development 16

Pipeline Products-Monotherapy 17

Pipeline Products-Combination Treatment Modalities 18

Pipeline Products-Partnered Products 19

Pipeline Products-Out-Licensed Products 21

Bristol-Myers Squibb Company-Pipeline Products Glance 23

Bristol-Myers Squibb Company-Late Stage Pipeline Products 23

Bristol-Myers Squibb Company-Clinical Stage Pipeline Products 26

Bristol-Myers Squibb Company-Early Stage Pipeline Products 31

Bristol-Myers Squibb Company-Drug Profiles 35

daclatasvir dihydrochloride 35

ipilimumab 38

nivolumab 41

daclatasvir dihydrochloride + asunaprevir 47

(daclatasvir dihydrochloride + asunaprevir + beclabuvir) 49

abatacept 51

apixaban 54

beclabuvir 56

brivanib alaninate 58

fostemsavir tromethamine 61

BMS-754807 63

BMS-813160 65

BMS-833923 66

BMS-919373 68

BMS-955176 69

BMS-986020 70

BMS-986036 71

dasatinib 73

denenicokin 76

eldelumab 78

lirilumab 80

lulizumab pegol 82

urelumab 83

BMS-911543 85

BMS-986004 87

BMS-986012 88

BMS-986148 89

BMS-986158 90

ulocuplumab 91

Antibody to Target CD40 Ligand for Immunology 93

BMS-241027 94

BMS-262084 96

BMS-777607 97

BMS-906024 98

BMS-962476 99

BMS-963272 100

BMS-981164 101

BMS-986016 102

BMS-986089 103

BMS-986090 104

BMS-986104 105

BMS-986115 106

BMS-986120 107

BMS-986141 108

BMS-986142 109

BMS-986147 110

BMS-986168 111

FLX-925 112

FS-102 113

Iso-fludelone 114

ixabepilone 116

MDX-1303 118

Small Molecule for Cancer 120

Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases 121

Small Molecule to Antagonize PAR4 for Thromboembolic Disorders 122

Small Molecule to Inhibit IRAK4 for Immunology 123

Small Molecule to Inhibit MGAT2 for Type 2 Diabetes and Obesity 124

BMS-817378 125

ALB-109780 126

AMR-2 127

ARX-720 129

BMS-457 130

BMS-585248 131

BMS-593214 132

BMS-795311 133

BMS-816106 134

BMS-869780 135

BMS-871 136

BMS-884775 137

Drug for Metabolic Disorders 138

F-001287 139

Small Molecule to Agonize Kv7.2 for Neuropathic Pain and Diabetic Neuropathy 140

Small Molecule to Antagonize Neuropeptide Y Receptor Y1 for Obesity 141

Small Molecule to Antagonize NK1R and Block SERT for Depression 142

Small Molecule to Inhibit Factor XIa for Thrombosis 143

Small Molecule to Inhibit IAP for Melanoma 144

Small Molecules to Antagonize NR2B for Major Depression 145

Small Molecules to Inhibit ROR-Gamma for Inflammation 146

Monoclonal Antibody Conjugates for Oncology 147

Proteins for Immunology and Cancer 148

Small Molecules for Undisclosed Indication 149

Small Molecules to Inhibit IDO and TDO for Oncology 150

Small Molecules to Inhibit IDO for Oncology 151

Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases 152

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders 153

Small Molecules to Inhibit TDO for Oncology 154

Bristol-Myers Squibb Company-Pipeline Analysis 155

Bristol-Myers Squibb Company-Pipeline Products by Target 155

Bristol-Myers Squibb Company-Pipeline Products by Route of Administration 166

Bristol-Myers Squibb Company-Pipeline Products by Molecule Type 167

Bristol-Myers Squibb Company-Pipeline Products by Mechanism of Action 168

Bristol-Myers Squibb Company-Recent Pipeline Updates 175

Bristol-Myers Squibb Company-Dormant Projects 214

Bristol-Myers Squibb Company-Discontinued Pipeline Products 219

Discontinued Pipeline Product Profiles 220

Bristol-Myers Squibb Company-Company Statement 225

Bristol-Myers Squibb Company-Locations And Subsidiaries 226

Head Office 226

Other Locations & Subsidiaries 226

Bristol-Myers Squibb Company-Key Manufacturing Facilities 231

Appendix 232

Methodology 232

Coverage 232

Secondary Research 232

Primary Research 232

Expert Panel Validation 232

Contact Us 232

Disclaimer 233

List of Tables

Bristol-Myers Squibb Company, Key Information 13

Bristol-Myers Squibb Company, Key Facts 13

Bristol-Myers Squibb Company-Pipeline by Indication, 2015 15

Bristol-Myers Squibb Company-Pipeline by Stage of Development, 2015 23

Bristol-Myers Squibb Company-Monotherapy Products in Pipeline, 2015 24

Bristol-Myers Squibb Company-Combination Treatment Modalities in Pipeline, 2015 25

Bristol-Myers Squibb Company-Partnered Products in Pipeline, 2015 26

Bristol-Myers Squibb Company-Partnered Products/ Combination Treatment Modalities, 2015 27

Bristol-Myers Squibb Company-Out-Licensed Products in Pipeline, 2015 28

Bristol-Myers Squibb Company-Out-Licensed Products/ Combination Treatment Modalities, 2015 29

Bristol-Myers Squibb Company-Pre-Registration, 2015 30

Bristol-Myers Squibb Company-Filing rejected/Withdrawn, 2015 31

Bristol-Myers Squibb Company-Phase III, 2015 32

Bristol-Myers Squibb Company-Phase II, 2015 33

Bristol-Myers Squibb Company-Phase I, 2015 35

Bristol-Myers Squibb Company-IND/CTA Filed, 2015 38

Bristol-Myers Squibb Company-Preclinical, 2015 39

Bristol-Myers Squibb Company-Discovery, 2015 41

Bristol-Myers Squibb Company-Pipeline by Target, 2015 162

Bristol-Myers Squibb Company-Pipeline by Route of Administration, 2015 173

Bristol-Myers Squibb Company-Pipeline by Molecule Type, 2015 174

Bristol-Myers Squibb Company-Pipeline Products by Mechanism of Action, 2015 175

Bristol-Myers Squibb Company-Recent Pipeline Updates, 2015 182

Bristol-Myers Squibb Company-Dormant Developmental Projects,2015 221

Bristol-Myers Squibb Company-Discontinued Pipeline Products, 2015 226

Bristol-Myers Squibb Company, Other Locations 233

Bristol-Myers Squibb Company, Subsidiaries 233

Bristol-Myers Squibb Company, Key Manufacturing Facilities 238

List of Figures

Bristol-Myers Squibb Company-Pipeline by Top 10 Indication, 2015 15

Bristol-Myers Squibb Company-Pipeline by Stage of Development, 2015 23

Bristol-Myers Squibb Company-Monotherapy Products in Pipeline, 2015 24

Bristol-Myers Squibb Company-Combination Treatment Modalities in Pipeline, 2015 25

Bristol-Myers Squibb Company-Partnered Products in Pipeline, 2015 26

Bristol-Myers Squibb Company-Out-Licensed Products in Pipeline, 2015 28

Bristol-Myers Squibb Company-Pipeline by Top 10 Target, 2015 162

Bristol-Myers Squibb Company-Pipeline by Top 10 Route of Administration, 2015 173

Bristol-Myers Squibb Company-Pipeline by Top 10 Molecule Type, 2015 174

Bristol-Myers Squibb Company-Pipeline Products by Top 10 Mechanism of Action, 2015 175

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Bristol-Myers Squibb Company; Bristol-Myers Squibb Company - Key Therapeutics; Bristol-Myers Squibb Company - Pipeline Overview and Promising Molecules; Bristol-Myers Squibb Company - News; Bristol-Myers Squibb Company - Latest Updates; Bristol-Myers Squibb Company - Pipeline; Bristol-Myers Squibb Company - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com